Abstract
microRNAs are promising drug targets in obesity and metabolic disorders. miR-21 expression is upregulated in obese white adipose tissue (WAT); however, its physiological role in WAT has not been fully explored. We aimed to dissect the underlying molecular mechanisms of miR-21 in treating obesity, diabetes, and insulin resistance. We demonstrated, in human and mice, that elevated miR-21 expression is associated with metabolically healthy obesity. miR-21 mimic affected the expression of genes associated with adipogenesis, thermogenesis, and browning in 3T3-L1 adipocytes. In addition, it blocked high fat diet-induced weight gain in obese mice, without modifying food intake or physical activity. This was associated with metabolic enhancements, WAT browning and thermogenic programming, and brown AT induction through VEGF-A, p53, and TGFβ1 signaling pathways. Our findings add a novel role of miR-21 in the regulation of obesity and a potential therapy for both obesity and T2D without altering caloric intake and physical activities.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The authors wish to thank all the subjects for their collaboration. CIBER Fisiopatologia de la Obesidad y Nutricion (CIBEROBN) is part of the Instituto de Salud del Carlos III (ISCIII). Project. This work was supported in part by grants from the Instituto de Salud Carlos III (ISCIII)/FEDER-UE (PI18/00785), Consejeria de Salud, Junta de Andalucia (PI-0092-2017), Spain and co-funded by the Fondo Europeo de Desarrollo Regional (FEDER). R.E.B. and F.J.B.S. are under a contract from the Nicolas Monarde (C-0030-2016, RC-0005-2016) program from the Servicio Andaluz de Salud, Regional Ministry of Health of the Andalusian Government, Andalusia, Spain. M.C.P. was a recipient of a post-doctoral grant Juan de la Cierva Formacion (FJCI-2017-32194) from the Ministerio de Ciencia, Innovacion y Universidades (Spain).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The experimental protocol was approved by the Ethics and Research Committee of the Virgen de la Victoria Clinical University Hospital (Malaga, Spain). The European Union recommendations (2010/63/EU) on animal experimentation were followed. All procedures were approved by the ethics committee of the University of Malaga (authorization no. 2012 0061A).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Yes data are available
